Blood Test May Help Predict Throat Cancer Linked To HPV.

In continuing coverage, Medscape (6/20, Chustecka) reports that approximately “one third of the patients who went on to develop oropharyngeal cancer associated with human papillomavirus type 16 (HPV 16) had antibodies to the virus detectable in their blood years before clinical diagnosis of the tumor,” according to research published online in the Journal of Clinical Oncology. This “finding could lead to the development of a screening tool, the researchers suggest.” The study’s lead author said, “Our study shows not only that the antibodies are present prior to diagnosis – but that in many cases, the antibodies are there more than a decade before the cancer is clinically detectable.” 

Compound Found In Naked Mole Rats May Protect Them From Cancer.

The New York Times (6/20, Zimmer, Subscription Publication, 1.68M) reports that, according to research published in Nature, “naked mole rats produce a unique compound that appears to block them from getting cancer.”

        Bloomberg News (6/20, Lopatto) reports that the compound, “called hyaluronan, exists between cells in tissue, helping to hold them together, according to the report in the journal Nature.” Although “all animals have hyaluronan, the mole rat’s version is unusually large: about five times the size of that found in humans.”

        On its website, CBS News (6/20, Jaslow) reports, “To see if the chemical was behind cancer protection, the scientists removed the substance from the mole rats’ cells. After, they found the cells were more prone to developing tumors, confirming the compound played some role in cancer protection.” The investigators “also found the gene responsible for making HMW-HA, called HAS2.”

        BBC News (6/20, Briggs) points out that “a similar version of the chemical is used as a medicine to treat arthritis and in anti-wrinkle jabs.” HealthDay (6/20, Gray) also covers the story.

Blood Test For Colon Cancer Shows Promise In Early Research.

HealthDay (6/20, Preidt) reports that a blood test for colon cancer has shown promise in early research. The test “checks for levels of miR-21 – a piece of DNA known as microRNA.” Investigators “found that measuring levels of miR-21 in the blood accurately spotted up to 92 percent of patients with colorectal cancer.” The researchers also found that “the test...accurately identified up to 82 percent of patients with advanced colorectal polyps – growths that put people at high risk of developing colorectal cancer.” The research was published in the Journal of the National Cancer Institute.

Immediate Post-Op IVC May Prevent Bladder Cancer Recurrence.

Renal and Urology News (6/19, Charnow, 16K) reports, “Intravesical chemotherapy (IVC) administered immediately following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer significantly decreases the likelihood of disease recurrence,” according to the findings of a new meta-analysis reported online in the journal European Urology. The analysis, “focused on 13 randomized, controlled trials that enrolled 2,548 adult patients. IVC immediately following TURBT significantly prolonged the recurrence-free interval (RFI) by 38%.”

Daratumumab Shows High, Durable Responses In Multiple Myeloma In Early Trial.

Medscape (6/19, McCall) reports, “The investigational daratumumab... has shown high and durable responses in multiple myeloma in a phase 1 trial.” At the 18th Congress of the European Hematology Association, researcher Henk Lokhorst, MD, said, “We’ve seen that 47% of patients showed benefit [with doses up to 24 mg/kg]. A response was seen in 8 of the 12 patients receiving more than 4 mg/kg, indicating that this dose provides a sufficient amount of daratumumab in the blood for an effective response.”

Pomalidomide Beneficial For Multiple Myeloma Patients In Phase 3 Trial.

Medscape (6/18, McCall) reports, “A combination of pomalidomide (Pomalyst) and low-dose dexamethasone in double-refractory multiple myeloma has shown ‘highly significant’ survival in a phase 3 trial.” The findings “from the large multicenter phase 3 study, known as the MM-003 trial” were presented “at the 18th Congress of the European Hematology Association.”

Radioimmunotherapy May Benefit Certain Patients With Lymphoma.

Medscape (6/15, Kling) reported that, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2013 Annual Meeting, “in patients with refractory or relapsed aggressive lymphoma, immunoradiation combined with high-dose chemotherapy is associated with better progression-free and overall survival than chemotherapy alone when used in advance of autologous stem cell transplantation.” Researchers came to this conclusion after conducting a trial in which “22 patients randomized to Z-BEAM were treated with BEAM plus ibritumomab tiuxetan 0.4 mCi/kg 14 days before transplantation,” while “21 patients in the control group were treated with BEAM alone.”

CS/HIPEC May Be Safe, Effective For Some Patients With Advanced Abdominal Cancers.

Medscape (6/17, Barclay) reported that, according to research published In Cancer Medicine, “cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS/HIPEC) appears to be safe and effective for select patients with advanced abdominal cancers.” Investigators came to this conclusion after “retrospectively review[ing] 112 patients undergoing CS/HIPEC from 2003 to 2011.”

Researchers Say SALL4 Gene May Be Marker For Aggressive Liver Cancer.

Medscape (6/14, Barclay) reports, “The discovery that an oncofetal gene, SALL4, appears to be a marker for aggressive liver cancer has ignited hope that it can be used to screen patients and that it will offer a new target for drug development.” The research was published in the New England Journal of Medicine. In an editorial accompanying the study, Jens U. Marquardt, MD, from the National Cancer Institute, and colleagues “call the study findings ‘convincing,’ but insufficient to determine whether the targeting of SALL4 alone has enough antitumor activity to prevent recurrent disease, or whether inhibition of the associated transcriptomic programs is also required.”

Trebananib, Chemotherapy Combo Lengthens Ovarian Cancer Survival.

The AP (6/13) reports Amgen Inc. announced Wednesday that its investigational ovarian cancer treatment, trebananib, in combination with paclitaxel, “helped patients live 1.8 months longer without their disease spreading, compared with patients getting placebo” plus paclitaxel, during a Phase IIIa trial comprising 900 study participants. The results released yesterday are from the “first of three” safety and efficacy trials Amgen is conducting on the treatment candidate for recurrent ovarian cancer.

        The Wall Street Journal (6/13, Warner, Subscription Publication, 2.29M) adds that Amgen said the trial results showed the group that was administered trebananib plus paclitaxel lived an additional 7.2 months without ovarian cancer progressing, whereas the progression-free survival (PFS) average for the arm that received a placebo plus paclitaxel was 5.4 months. The difference was considered statistically significant and means the primary end goal for PFS was achieved, the Thousand Oaks, California-based biopharmaceutical company noted. Amgen said it expects to release data on overall survival, the primary secondary endpoint, in 2014.

        Also covering the positive, interim trial results is Reuters (6/13, Humer, Beasley).

Early Data Indicate Modified Poliovirus May Benefit Patients With Glioblastoma.

Oncology Nurse Advisor (6/12, Boltz) reports that “attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study.” Researchers “previewed the results of seven participants enrolled in the” phase I study. The data indicate that “one patient remains disease-free 12 months after treatment, another 11 months posttreatment and the third is disease-free after five months.” The research was presented at the American Society of Clinical Oncology meeting.

Study Shows Novel Hsp Inhibitor May Improve Survival In Patients With NSCLC.

OncLive (6/8, Broderick) reported that “salvage therapy combining the novel heat shock protein 90 (Hsp90) inhibitor ganetespib with docetaxel significantly improved overall survival (OS) in some patients with non–small cell lung cancer (NSCLC) in the phase IIb/III GALAXY-1 trial.” The results “were presented at a press conference at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).” Marjorie G. Zauderer, MD, an ASCO spokesperson, explained, “This research unto itself isn’t practice changing, but I think it does merit further investigation in this prespecified subgroup [of patients >6 months postdiagnosis].”

Researchers Analyze Uterine Fibroids.

Medscape (6/8, Lewis) reported, “Whole-genome sequencing and gene expression profiling of uterine fibroids has uncovered a chromosome-shattering process formerly associated only with aggressive cancers, according to a study published online June 5 in the New England Journal of Medicine.” Investigators “analyzed 38 uterine leiomyomas and the myometrium from 30 women.” The researchers found that “sixteen of the leiomyomas had mutations in the MED12 oncogene that regulates transcription, 4 leiomyomas had loss-of-function mutations in the tumor suppressor gene that encodes fumarate hydratase (part of the citric acid cycle), and the other 18 leiomyomas did not have either of these previously identified mutations.”

        MedPage Today (6/9, Bankhead) reported, “The investigation also identified” complex chromosomal rearrangement “events that resulted in changes consistent with an initiating (driver) role in leiomyomas. For example, two samples had rearrangements between chromosomes 12 and 14 that arose from the CCR event. In another sample, a CCR event led to rearrangement of HMGA2 to chromosome 5.”

Trichloroethylene May Be Linked To Higher Risk Of Liver, Cervical Cancer.

Reuters (6/7, Doyle) reports that, according to research published in the Journal of the National Cancer Institute, the industrial chemical solvent trichloroethylene (TCE) exposure may be linked to an increased risk of liver cancer and cervical cancer. Investigators came to this conclusion after looking at data from three studies that included more than 5,500 individuals who had been exposed to the chemical.


Contraceptives May Be Linked To Reduced Risk Of Ovarian Cancer.

Reuters (6/7, Pittman) reports that, according to research published online in Obstetrics & Gynecology, the use of oral contraceptives may be linked to a reduced risk of ovarian cancer. Investigators came to this conclusion after analyzing data from 24 studies.


Adding Curcuminoids To Docetaxel May Benefit Certain Prostate Cancer Patients.

The Cancer Network (6/6, Kaufman) reports, “Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel ‘in terms of both PSA decrease and objective response’ in a phase II trial in patients with castration-resistant prostate cancer (CRPC).” The findings were presented at the ASCO meeting. “Four complete PSA responses and 13 partial responses were observed in 17 of 29 patients (59%).”


Medication Developed For Melanoma Demonstrates Activity In Some NSCLC Patients.

MedPage Today (6/6, Bankhead) reports that a medication “developed for melanoma has demonstrated activity in a subgroup of patients with non-small cell lung cancer (NSCLC),” according to research presented at the American Society of Clinical Oncology meeting. Researchers found that “eight of 20 patients had objective responses to treatment with dabrafenib (Tafinlar), an inhibitor of the BRAF V600E mutation.” This research “provided the first evidence that BRAF V600E is a viable therapeutic target in NSCLC, as it is in melanoma.”


Experimental Medication Shows Promising Activity, Safety Against NSCLC.

MedPage Today (6/6, Smith) reports, “One of the entrants in a new class of cancer immunotherapies had promising activity and safety against non-small cell lung cancer, a researcher reported” at the American Society of Clinical Oncology meeting. During “an early clinical trial, the drug – an antibody to a protein called PD-L1 – led to tumor shrinkage or stable disease in nearly half of a cohort of heavily pre-treated patients, according to David Spigel, MD.” The medication, currently called MPDL3280A, “was also well tolerated, with severe adverse events seen in about a third of patients, Spigel reported.”


HPV, P16 Expression Linked To Better Response, OS In Certain SCCHN Patients.

HemOnc Today (6/6, 33K) reports, “The presence of HPV and tumor p16 status were associated with significant improvements in objective response and OS among patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to study results presented at the ASCO Annual Meeting.” Additionally, the investigators “examined excision repair cross-complementation group 1 (ERCC1) tumor expression, and” they found that “ERCC1 low status was associated with a trend toward better OS.”


Sunitinib May Delay Relapse After Chemo For Small Cell Lung Cancer.

MedPage Today (6/6, Smith) reports, “Maintenance therapy with the oral tyrosine kinase inhibitor sunitinib (Sutent) delayed relapse after chemotherapy in patients with extensive small cell lung cancer, a researcher said” at the American Society of Clinical Oncology meeting. The medication, “in a randomized, placebo-controlled phase II trial...increased progression-free survival by 53%, according to Neal Ready, MD.” Additionally, “there was...a trend toward better overall survival, although patients who progressed on placebo were allowed to cross over to sunitinib, Ready reported.”


Novel Agent May Boost Chemo In Patients With CLL.

MedPage Today (6/6, Phend) reports that research presented at the American Society of Clinical Oncology meeting suggests that “adding the novel anti-CD20 agent obinutuzumab to standard chemotherapy for older, sicker patients with chronic lymphocytic leukemia improves outcomes, possibly more so than adding rituximab (Rituxan).” Researchers found that “the combination with obinutuzumab (also known as GA101) was associated with more than double the progression-free survival of chlorambucil (Leukeran) alone – 23 months versus 10.9 (P<0.0001).” While “no patient had a complete response with chemotherapy alone, but 22% who got the monoclonal antibody did.”


Majority Of Patients With Advanced, Mutated NSCLC Responded To LDK378.

MedPage Today (6/5, Bankhead) reports, “A majority of patients with advanced, mutated non-small cell lung cancer (NSCLC) responded to an investigational therapy, including tumors resistant to an agent that targets the mutation,” in a study presented at the American Society of Clinical Oncology meeting. Investigators found that “treatment with LDK378 led to an overall response rate of 60% to 78% in 114 patients with anaplastic lymphoma kinase (ALK) gene mutations.” The Majority of “the patients had previously been treated with the first-generation ALK inhibitor crizotinib (Xalkori).”

        HemOnc Today (6/5, 33K) reports, “Patients with and without crizotinib resistance experienced responses, as did patients with untreated metastases in the central nervous system.”


Nintedanib May Slightly Delay Relapse Of NSCLC When Added To Chemo.

MedPage Today (6/5, Phend) reports, “The novel kinase inhibitor nintedanib may slightly delay relapse of non-small cell lung cancer (NSCLC) when added to chemotherapy, with perhaps greater benefit in adenocarcinomas,” according to research presented at the American Society of Clinical Oncology meeting. Researchers found that “the angiogenesis-targeted agent prolonged progression-free survival (PFS) by an average of 3 weeks, a 21% improvement over the median 2.7 months with docetaxel alone (P=0.0019).”

Everolimus May Extend Time Before Relapse In Patients Resistant To Trastuzumab.

MedPage Today (6/5, Smith) reports that research presented at the American Society of Clinical Oncology meeting “may help unravel the issue of resistance to a drug that is central to the treatment of HER2-positive breast cancer.” Data from “the BOLERO-3 trial” indicated that “everolimus (Afinitor) significantly extended the time before relapse in patients resistant to trastuzumab (Herceptin), reported Ruth O’Regan.” Additionally, “there were...fewer deaths among women treated with the drug, although the researchers have not yet completed a formal assessment of overall survival, O’Regan reported.” 

Cetuximab May Increase Survival In Metastatic Colorectal Cancer.

MedPage Today (6/4, Bankhead) reports, “Survival in metastatic colorectal cancer increased significantly despite no slowing of tumor growth when one targeted agent – cetuximab (Erbitux) was added to first-line chemotherapy but there was no benefit when another targeted therapy was tried,” according to research presented at the American Society of Clinical Oncology meeting. Researchers found that “the combination of cetuximab (Erbitux) and FOLFIRI chemotherapy (5-FU, folinic acid, and irinotecan) achieved almost a 4-month advantage over the combination of bevacizumab (Avastin) and FOLFIRI,” but “patients treated with either had similar objective response rates – the primary endpoint – as well as similar progression-free survival (PFS).”

Virus-Derived Talimogene Laherparepvec May Benefit Patients With Melanoma.

MedPage Today (6/4, Bankhead) reports, “Intralesional injection of an oncolytic therapy significantly increased the durable response rate in advanced melanoma compared with a control therapy, according to” research presented at the ASCO meeting. Researchers found that “patients treated with the virus-derived talimogene laherparepvec (T-VEC) had a 16.3% rate of durable responses, defined as partial or complete response maintained for at least 6 months. That compared with 2% of patients treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) who had durable responses.”

Lapatinib Fails To Increase Gastric Cancer Survival.

Reuters (6/4, Sandle) reports that lapatinib combined with chemo failed to increase survival rates in individuals with gastric cancer, compared to chemo alone, according to the drug’s maker, GlaxoSmithKline.

Study: Experimental Medication Shrinks Tumors In 38 Percent Of Patients With Advanced Melanoma.

The New York Times (6/3, Pollack, Subscription Publication, 1.68M) reports, “An experimental drug from Merck that unleashes the body’s immune system significantly shrank tumors in 38 percent of patients with advanced melanoma, putting the company squarely in the race to bring to market one of what many experts view as the most promising class of drugs in years.” The study, published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology meeting, found that “while tumors shrank in 38 percent of the patients over all, the rate was 52 percent for patients who got the highest dose of the drug, which is called lambrolizumab, or MK-3475.”

        Reuters (6/3, Steenhuysen) reports that recently, the FDA deemed the medication a “breakthrough therapy,” which the FDA’s Dr. Richard Pazdur called “knock-your-socks-off therapies.” Also covering the story are Forbes (6/2, 928K), XConomy (6/2, Timmerman), The Street (6/3, Feuerstein), MedPage Today (6/3, Smith), HealthDay (6/3, Reinberg), and Fierce Biotech (6/3, Hollmer)

Sorafenib May Increase PFS In Patients With Advanced Thyroid Cancer.

The Wall Street Journal (6/3, Walker, Subscription Publication, 2.29M) reports that in a study presented at the American Society of Clinical Oncology meeting, researchers found that Nexavar (sorafenib)may increase progression-free survival in certain patients with thyroid cancer. However, the medication did not increase overall survival.

        Bloomberg News (6/2, Kresge) reports, “Bayer said it plans to request marketing approval in thyroid cancer soon in the U.S. and Europe.” Reuters (6/2) and HealthDay (6/3, Norton) also cover the story.

Longer Tamoxifen Use May Be Linked To Lower Risk Of Breast Cancer Recurrence.

Reuters (6/2, Beasley) reports that, according to research presented at the American Society of Clinical Oncology meeting, breast cancer recurrence may be more likely if women who had been treated for breast cancer in the past take tamoxifen for a full decade rather than just five years. This study is part of a larger study. Similar findings were reported in 2012 for that study. ASCO President Dr. Sandra Swain called the finding “huge.”

        HealthDay (6/3, Mozes) reports, “When it comes to using the drug tamoxifen to prevent breast cancer’s return, longer may be better for some patients,” according to a study presented at the ASCO meeting. Researchers found that “women combating estrogen-sensitive breast tumors fared better when treated with 10 years of tamoxifen compared to those given the current standard of five years.” In an ASCO news release, Dr. Sylvia Adams, an ASCO spokesperson, said, “These results are therefore practice-changing for premenopausal women with hormone receptor-positive breast cancer and especially relevant for women who are at high risk of recurrence.”

Vinegar May Help Reduce Deaths From Cervical Cancer.

The Wall Street Journal (6/2, Loftus, Subscription Publication, 2.29M) reports that, according to research presented at the American Society of Clinical Oncology meeting, vinegar may reduce deaths from cervical cancer in some countries. The US National Institutes of Health provided funding for the study.

        Reuters (6/3, Steenhuysen) reports that according to Electra Paskett, an ASCO spokeswoman, “What we’re talking about is the use of vinegar in a large screening program where PAP testing is not available. There have been studies that have demonstrated that the accuracy of these programs is comparable.”

Adding White-Blood Cell Boosting Treatment To Ipilimumab May Benefit Patients With Advanced Skin Cancer.

Bloomberg News (6/2, Langreth) reports, “Adding a white-blood cell boosting treatment from Sanofi (SAN) to Bristol-Myers Squibb Co. (BMY)’s (BMY) melanoma drug Yervoy [ipilimumab] helped patients with advanced skin cancer live longer and lessened side effects,” according to research presented at the American Society of Clinical Oncology meeting. Investigators found, “in the trial of 245 patients,” that “68.9 percent of patients who got Yervoy, designed to spur the immune system to attack cancer cells, and the Sanofi (SAN) drug, GM-CSF, were alive one year later, compared to 52.9 percent of those who got Yervoy alone.”

Pazopanib May Increase PFS In Patients With Advanced Ovarian Cancer.

The New York Times (6/2, Pollack, Subscription Publication, 1.68M) reports that a study presented at the American Society of Clinical Oncology annual meeting suggested that “women with ovarian cancer may be able to stave off relapses for an extra half-year or so by taking a drug already approved to treat kidney cancer,” pazopanib, sold by GlaxoSmithKline as Votrient.

        Bloomberg News (6/2, Kitamura) reports, “Disease progression was delayed for a median of 17.9 months among patients taking Votrient, compared with 12.3 months among those on placebo, according to the study of 940 patients with advanced ovarian, Fallopian tube and primary peritoneal cancer.”

        Reuters (6/2, Beasley) reports, however, that the medication did not seem to have an impact on overall survival.

        OncLive (6/2, Incollingo) reports, “‘Relapses remain all too common for women with advanced ovarian cancer. This large trial shows us that targeting multiple molecular cancer drivers can have a substantial impact on this cancer’s ability to grow, giving our patients significantly longer time before relapse. This study offers a real-world example of how the precision medicine era of cancer research is paying off in areas where no alternate approved drugs exist,’ said Carol Aghajanian, MD, ASCO spokesperson and gynecologic cancers expert and chief of Gynecologic Medical Oncology Service at Memorial Sloan-Kettering Cancer Center in New York, New York.”

        HealthDay (6/2, Thompson) points out, however, that “there are drawbacks. For one, Votrient is a costly drug. Online pharmacies charge around $1,900 for 30 200-milligram tablets of the medication.” Additionally, “one of every four ovarian cancer patients taking pazopanib reported unpleasant side effects, including hypertension, diarrhea, nausea, headache and fatigue.” Also covering the story are HemOnc Today (6/2, 33K) and Medscape (6/2, Nelson).

Selumetinib May Benefit Patients With Advanced Uveal Melanoma.

Reuters (6/2, Steenhuysen) reports that, for the first time ever, a clinical trial indicated that a medication helped individuals suffering from advanced uveal melanoma. The research was presented at the American Society of Clinical Oncology meeting.

        MedPage Today (6/2) reports, “Half of patients on selumetinib saw their tumor shrink at least somewhat compared with 11% on temozolomide (Temodar), a standard chemotherapy used for skin melanoma, Richard Carvajal, MD, of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues found.” The data indicated that “fully 15% of patients had at least a 30% reduction in tumor volume on the novel drug compared with none on temozolomide.” Additionally, “progression-free survival was...54% better with the agent than with temozolomide (16 versus 7 weeks, P=0.0003).”

        Medscape (6/2, Chustecka) reports that ASCO spokesperson and melanoma expert Lynn Schuchter, MD, “predicted that these data will ultimately be practice changing, adding: ‘A MEK inhibitor will be used in the treatment of this disease, whether it is this one or another one.’”

        The Street (6/2, Feuerstein) reports, however, that “selumetinib failed to demonstrate significant efficacy in the more widely diagnosed skin melanoma.”

        OncLive (6/2) features a video in which Dr. Carvajal discusses this research and related research.

        AFP (6/2, Oberman) also reports on the selumetinib study, as well on the nivolumab and ipilimumab studies.


Superfoods May Benefit Patients With Prostate Cancer.

The Daily Telegraph (UK) (6/2, Donnelly, 871K) reports that, according to research scheduled to be presented at the American Society of Clinical Oncology meeting, “superfoods” may benefit patients with prostate cancer. In the study, “men who had been treated with surgery or radiotherapy for the disease were given a capsule containing essence of pomegranate, green tea, turmeric and broccoli.” The researchers found, “at the end of a six-month trial,” that “their PSA levels...were 63 per cent lower than those who took a placebo.”


PBT-IACT May Be As Effective As Surgery For Certain Patients With Tongue Cancer.

Oncology Nurse Advisor (6/2, Dantoni) reports, “Proton beam therapy (PBT) combined with selective intra-arterial infusion chemotherapy (IACT) appears to be as safe and effective as surgery in treating locally advanced tongue cancer, researchers reported in a study presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.” According to the researchers, “PBT-IACT appeared to be safe and had a good OS and LC rate for locally advanced tongue cancer. Furthermore, it is not inferior to surgery and can be one of the new effective treatment options for inoperable/locally advanced tongue cancer.”


HPV-Oral Cancer May Post Little Threat To Spouses.

MedPage Today (6/1, Phend) reports, “Oropharyngeal cancers that arise from human papillomavirus (HPV) are no more likely to spread to a domestic partner than to the general population,” according to research presented at the American Society of Clinical Oncology meeting. Researchers found that “HPV prevalence among spouses or partners of an affected patient was similar to that of the general population, at 7%.” While “spouses are very anxious about their own chances of getting HPV-related cancer, the actual risk appears low for head and neck cancers, the group suggested.”



Captavi QixSuite™ - Hosted Marketing Automation Software ©